GlassScriptPhysician profile
Natsuko Okamura
NPI 1588933782
$3,099.23
in general payments reported to CMS, 2019-2025
22 companies · $1,129 in 2025
The $1,129 reported for 2025 was more than what 88% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $396 · 2022: $138 · 2023: $1,038 · 2024: $399 · 2025: $1,129.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,500 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,499.62 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $489.43 | 2023-2025 | Breztri, Farxiga, Airsupra |
| Abbvie INC. | $389.15 | 2022-2025 | |
| Astellas Pharma US INC | $258.83 | 2022-2025 | Veozah, Myrbetriq |
| Amgen INC. | $242.75 | 2021-2023 | Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $157.48 | 2021-2024 | Jardiance, Tradjenta |
| Corium, LLC | $147.32 | 2023 | Adlarity |
| Medtronic, INC. | $147.12 | 2025 | Avalus, Inceptiv |
| Bayer Healthcare Pharmaceuticals INC. | $144.40 | 2023-2025 | |
| Procept Biorobotics Corporation | $136.93 | 2024 | Aquabeam System |
| Lilly USA, LLC | $135.39 | 2023-2025 | Jardiance, Mounjaro, Zepbound |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $125.00 | 2025 | Caplyta |
| Eisai INC. | $125.00 | 2025 | |
| Glaxosmithkline, LLC. | $123.27 | 2021-2025 | Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $115.63 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $105.89 | 2023 | Rexulti |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $92.11 | 2021 | |
| Abbott Laboratories | $68.65 | 2021-2024 | Freestyle Libre 3, Eterna |
| Novartis Pharmaceuticals Corporation | $25.23 | 2025 | |
| Exact Sciences Corporation | $21.45 | 2025 | The Cologuard Plus Collection Kit |
| Novo Nordisk INC | $19.46 | 2025 | Ozempic |
| Pfizer INC. | $16.87 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Natsuko Okamura listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.